Kadmon gains after announcing expiry of HSR waiting period for Sanofi deal
- BySeeking Alpha-
Sanofi (SNY) has got one step closer to complete its acquisition of Kadmon Holdings
Sanofi (SNY) has got one step closer to complete its acquisition of Kadmon Holdings
Here's a roundup of top ...Full story available on Benzinga.com
Biotech stocks rebounded in the week ended Oct. 15, bouncing from third straight weekly losses. The strength came amid a broader market rally and some sector-specific...
Pfizer Submits Vaccine Trial Data For Kids As Young As 5; Sanofi Abandons Development Of mRNA JabYesterday while receiving his Pfizer booster jab during a live-streamed media...
France's Sanofi will acquire Kadmon Holdings of New York City in a $1.9 billion deal. In 2019, Kadmon formed a JV with BioNova Pharma to develop its novel lead drug, Rezurock...
Sanofi has entered into a definitive agreement with Translate Bio for $38.00 per share in cash, which represents a total equity value of $3.2B a fully diluted basis.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Buy | Buy | Strong Buy | Buy |
| Technical Indicators | Strong Sell | Buy | Strong Buy | Strong Buy | Strong Buy |
| Summary | Strong Sell | Buy | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 91.00 | 91.50 | 89.30 | +0.10 | +0.11% | 3.50M | London | |||
| 156.06 | 161.40 | 154.80 | -4.10 | -2.56% | 24.09M | London | |||
| 257.70 | 258.50 | 255.30 | +1.50 | +0.58% | 1.62M | London | |||
| 434.80 | 437.95 | 432.25 | +0.05 | +0.01% | 19.56M | London | |||
| 293.60 | 296.00 | 292.70 | -2.60 | -0.88% | 1.53M | London | |||
| 355.00 | 358.80 | 352.00 | -1.20 | -0.34% | 23.65M | London | |||
| 110.82 | 111.40 | 110.06 | -0.06 | -0.05% | 32.55M | London | |||
| 375.00 | 378.00 | 370.00 | +3.00 | +0.81% | 118.93K | London | |||
| 589.60 | 593.40 | 585.20 | +4.20 | +0.72% | 8.92M | London | |||
| 21.92 | 22.54 | 21.90 | -0.54 | -2.40% | 176.59K | London | |||
| 449.00 | 457.50 | 443.00 | -8.00 | -1.75% | 233.62K | London | |||
| 106.50 | 108.00 | 106.80 | +1.30 | +1.24% | 322.11K | London | |||
| 5.14 | 5.22 | 5.06 | +0.11 | +2.15% | 632.30K | London | |||
| 2,328.00 | 2,352.00 | 2,300.00 | -8.0 | -0.34% | 73.85K | London | |||
| 135.10 | 139.06 | 135.08 | -2.90 | -2.10% | 20.87M | London |
Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.